Related Experiment Video
Updated: Sep 22, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
How do we manage t(11;14) plasma cell disorders with venetoclax?
Rajshekhar Chakraborty1, Divaya Bhutani1, Suzanne Lentzsch1
1Multiple Myeloma and Amyloidosis Program, Columbia University Irving Medical Center, New York, New York, USA.
Abstract:
The oral BCL-2 inhibitor venetoclax has demonstrated promising efficacy in patients with t(11;14) plasma cell disorders, both as a single-agent and in combination. However, there was an increased mortality signal in the randomized BELLINI trial that was primarily driven by non-t(11;14) patients. Based on current evidence, venetoclax is included as an option for relapsed/refractory t(11;14) plasma cell dyscrasias in NCCN guidelines and is being widely used in clinical practice. In this review, we aim to critically appraise the current literature and perform case-based illustration of our approach to management of t(11;14) plasma cell disorders with venetoclax.
More Related Videos
Related Concept Videos
Venous Thrombosis IV: Nursing Management
Venous Thrombosis III: Interprofessional Care
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Continuous Renal Replacement Therapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
